PREVIEW-Warner Chilcott Q1 to beat Street on acne drug sales

viernes 8 de mayo de 2009 21:17 CEST
 

* What: Q1 results

* When: Monday, May 11

* Q1 expected to top estimates

* Doryx sales to drive results

* Oral contraceptives sales to slow down

By Vidya L Nathan

BANGALORE, May 8 (Reuters) - Higher sales of Doryx, an acne product, are expected to push specialty pharmaceutical company Warner Chilcott Ltd's WCRX.O first-quarter results above market expectations.

Increasing prescriptions of Doryx will likely more than offset slowing sales of the company's oral contraceptives, such as Loestrin 24 Fe and Ovcon 50, which have been trying to stave off competition from cheaper generics.

"I think Doryx is a source of upside because they have been shifting to the 150 milligram dose, which has a higher value per prescription," Leerink Swann analyst Gary Nachman said.   Continuación...